Lignocaine pretreatment for suxamethonium. A clinicobiochemical study.
Lignocaine pretreatment (2 mg/kg) significantly restricted the increase in serum potassium and decrease in serum calcium caused by suxamethonium. Suxamethonium muscle pains occurred in only 8% of patients who received lignocaine just before induction of anaesthesia. The incidence of muscle pains was 45% in those patients who were not given lignocaine.
D000293:Adolescent; D000328:Adult; D002118:Calcium / Q000097:blood; D005260:Female; D006801:Humans; D008012:Lidocaine; D008297:Male; D008875:Middle Aged; D009135:Muscular Diseases / Q000139:chemically induced / Q000517:prevention & control; D010149:Postoperative Pain / Q000139:chemically induced / Q000517:prevention & control; D011188:Potassium / Q000097:blood; D011229:Preanesthetic Medication; D013390:Succinylcholine / Q000009:adverse effects*
D008012:Lidocaine; D013390:Succinylcholine; D011188:Potassium; D002118:Calcium